•
Dec 31, 2020

DexCom Q4 2020 Earnings Report

Dexcom's Q4 2020 financial results were reported, showing revenue growth and strategic advancements.

Key Takeaways

Dexcom reported a strong Q4 2020 with a 23% increase in revenue to $568.9 million compared to the same quarter of the prior year. GAAP operating income was $104.0 million, representing 18.3% of revenue.

Revenue grew by 23% to $568.9 million compared to Q4 2019.

U.S. revenue increased by 20%, while international revenue grew by 35%.

GAAP operating income was $104.0 million, or 18.3% of revenue.

GAAP net income was $355.2 million, or $3.48 per diluted share.

Total Revenue
$569M
Previous year: $463M
+22.9%
EPS
$0.23
Previous year: $0.29
-20.7%
Gross margin
70.2%
Previous year: 66.8%
+5.1%
Operating margin
18.3%
Previous year: 21.9%
-16.4%
Gross Profit
$399M
Previous year: $309M
+29.0%
Cash and Equivalents
$818M
Previous year: $446M
+83.2%
Free Cash Flow
$112M
Previous year: $99.6M
+12.2%
Total Assets
$4.29B
Previous year: $2.4B
+79.1%

DexCom

DexCom

DexCom Revenue by Segment

DexCom Revenue by Geographic Location

Forward Guidance

The company is reiterating guidance for fiscal year 2021 revenue, and establishing guidance for full year gross profit, operating margin, and Adjusted EBITDA margin as follows: Revenue of approximately $2.21 - 2.31 billion (15-20% growth), Non-GAAP Gross profit margin of approximately 65%, Non-GAAP Operating margin of approximately 13%, Adjusted EBITDA margin of approximately 23%

Positive Outlook

  • Revenue of approximately $2.21 - 2.31 billion (15-20% growth)
  • Non-GAAP Gross profit margin of approximately 65%
  • Non-GAAP Operating margin of approximately 13%
  • Adjusted EBITDA margin of approximately 23%

Revenue & Expenses

Visualization of income flow from segment revenue to net income